Gene expression markers in circulating tumor cells may predict bone metastasis and response to hormonal treatment in breast cancer

Wang,Haiying; Molina,Julian; Jiang,John; Ferber,Matthew; Pruthi,Sandhya; Jatkoe,Timothy; Derecho,Carlo; Rajpurohit,Yashoda; Zheng,Jian; Wang,Yixin

doi:10.3892/mco.2013.163

Gene expression markers in circulating tumor cells may predict bone metastasis and response to hormonal treatment in breast cancer

Authors:
- Haiying Wang
- Julian Molina
- John Jiang
- Matthew Ferber
- Sandhya Pruthi
- Timothy Jatkoe
- Carlo Derecho
- Yashoda Rajpurohit
- Jian Zheng
- Yixin Wang
View Affiliations

Affiliations: Veridex/Ortho‑Clinical Diagnostics, Inc., Johnson & Johnson, Raritan, NJ 08869, USA, Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA, Department of Breast Clinic, Mayo Clinic, Rochester, MN 55905, USA
Published online on: August 2, 2013 https://doi.org/10.3892/mco.2013.163
Pages: 1031-1038

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Circulating tumor cells (CTCs) have recently attracted attention due to their potential as prognostic and predictive markers for the clinical management of metastatic breast cancer patients. The isolation of CTCs from patients may enable the molecular characterization of these cells, which may help establish a minimally invasive assay for the prediction of metastasis and further optimization of treatment. Molecular markers of proven clinical value may therefore be useful in predicting disease aggressiveness and response to treatment. In our earlier study, we identified a gene signature in breast cancer that appears to be significantly associated with bone metastasis. Among the genes that constitute this signature, trefoil factor 1 (TFF1) was identified as the most differentially expressed gene associated with bone metastasis. In this study, we investigated 25 candidate gene markers in the CTCs of metastatic breast cancer patients with different metastatic sites. The panel of the 25 markers was investigated in 80 baseline samples (first blood draw of CTCs) and 30 follow‑up samples. In addition, 40 healthy blood donors (HBDs) were analyzed as controls. The assay was performed using quantitative reverse transcriptase polymerase chain reaction (qRT‑PCR) with RNA extracted from CTCs captured by the CellSearch system. Our study indicated that 12 of the genes were uniquely expressed in CTCs and 10 were highly expressed in the CTCs obtained from patients compared to those obtained from HBDs. Among these genes, the expression of keratin 19 was highly correlated with the CTC count. The TFF1 expression in CTCs was a strong predictor of bone metastasis and the patients with a high expression of estrogen receptor β in CTCs exhibited a better response to hormonal treatment. Molecular characterization of these genes in CTCs may provide a better understanding of the mechanism underlying tumor metastasis and identify gene markers in CTCs for predicting disease progression and response to treatment.

View Figures

View References

1.	Weigelt B, Peterse JL and van ‘t Veer LJ: Breast cancer metastasis: markers and models. Nat Rev Cancer. 5:591–602. 2005. View Article : Google Scholar : PubMed/NCBI
2.	Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW and Hayes DF: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 351:781–791. 2004. View Article : Google Scholar : PubMed/NCBI
3.	Smirnov DA, Zweitzig DR, Foulk BW, Miller MC, Doyle GV, Pienta KJ, Meropol NJ, Weiner LM, Cohen SJ, Moreno JG, Connelly MC, Terstappen LW and O’Hara SM: Global gene expression profiling of circulating tumor cells. Cancer Res. 65:4993–4997. 2005. View Article : Google Scholar : PubMed/NCBI
4.	Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, Doyle GV, Matera J, Allard WJ, Miller MC, Fritsche HA, Hortobagyi GN and Terstappen LW: Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol. 23:1420–1430. 2005. View Article : Google Scholar
5.	Sieuwerts AM, Mostert B, Bolt-de Vries J, et al: mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients. Clin Cancer Res. 17:3600–3618. 2011. View Article : Google Scholar : PubMed/NCBI
6.	Smid M, Wang Y, Klijn JG, Sieuwerts AM, Zhang Y, Atkins D, Martens JW and Foekens JA: Genes associated with breast cancer metastatic to bone. J Clin Oncol. 24:2261–2267. 2006. View Article : Google Scholar : PubMed/NCBI
7.	Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordón-Cardo C, Guise TA and Massagué J: A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 3:537–549. 2003. View Article : Google Scholar : PubMed/NCBI
8.	Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL and Massagué J: Genes that mediate breast cancer metastasis to lung. Nature. 436:518–524. 2005. View Article : Google Scholar : PubMed/NCBI
9.	Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, Nguyen DX, Minn AJ, van de Vijver MJ, Gerald WL, Foekens JA and Massagué J: Genes that mediate breast cancer metastasis to the brain. Nature. 459:1005–1009. 2009. View Article : Google Scholar : PubMed/NCBI
10.	Saloustros E, Perraki M, Apostolaki S, Kallergi G, Xyrafas A, Kalbakis K, Agelaki S, Kalykaki A, Georgoulias V and Mavroudis D: Cytokeratin-19 mRNA-positive circulating tumor cells during follow-up of patients with operable breast cancer: prognostic relevance for late relapse. Breast Cancer Research. 13:R602011. View Article : Google Scholar
11.	Reinholz MM, Nibbe A, Jonart LM, Kitzmann K, Suman VJ, Ingle JN, Houghton R, Zehentner B, Roche PC and Lingle WL: Evaluation of a panel of tumor markers for molecular detection of circulating cancer cells in women with suspected breast cancer. Clin Cancer Res. 11:3722–3732. 2005. View Article : Google Scholar : PubMed/NCBI
12.	Speirs V: Oestrogen receptor beta in breast cancer: good, bad or still too early to tell? J Pathol. 197:143–147. 2002. View Article : Google Scholar : PubMed/NCBI
13.	Lee GS, Choi KC, Kim HJ and Jeung EB: Effect of genistein as a selective estrogen receptor beta agonist on the expression of calbindin-D9k in the uterus of immature rats. Toxicological Sci. 82:451–457. 2004. View Article : Google Scholar : PubMed/NCBI
14.	Hartman J, Ström A and Gustafsson JA: Estrogen receptor beta in breast cancer - diagnostic and therapeutic implications. Steroids. 74:635–641. 2009. View Article : Google Scholar : PubMed/NCBI
15.	Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, Matera J, Allard WJ, Doyle GV and Terstappen LW: Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res. 12:4218–4224. 2006. View Article : Google Scholar
16.	O’Hara SM, Moreno JG, Zweitzig DR, Gross S, Gomella LG and Terstappen LW: Multigene reverse transcription-PCR profiling of circulating tumor cells in hormone-refractory prostate cancer. Clin Chem. 50:826–835. 2004.PubMed/NCBI
17.	Ring AE, Zabaglo L, Ormerod MG, Smith IE and Dowsett M: Detection of circulating epithelial cells in the blood of patients with breast cancer: comparison of three techniques. Br J Cancer. 92:906–912. 2005. View Article : Google Scholar : PubMed/NCBI
18.	Ghadersohi A and Sood AK: Prostate epithelium-derived Ets transcription factor mRNA is overexpressed in human breast tumors and is a candidate breast tumor marker and a breast tumor antigen. Clin Cancer Res. 7:2731–2738. 2001.
19.	Ignatiadis M, Kallergi G, Ntoulia M, Perraki M, Apostolaki S, Kafousi M, Chlouverakis G, Stathopoulos E, Lianidou E, Georgoulias V and Mavroudis D: Prognostic value of the molecular detection of circulating tumor cells using a multi-marker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer. Clin Cancer Res. 14:2593–2600. 2008. View Article : Google Scholar
20.	Xenidis N, Ignatiadis M, Apostolaki S, Perraki M, Kalbakis K, Agelaki S, Stathopoulos EN, Chlouverakis G, Lianidou E, Kakolyris S, Georgoulias V and Mavroudis D: Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. J Clin Oncol. 27:2177–2184. 2009. View Article : Google Scholar : PubMed/NCBI
21.	Knowlden JM, Gee JM, Robertson JF, Ellis IO and Nicholson RI: A possible divergent role for the oestrogen receptor alpha and beta subtypes in clinical breast cancer. Int J Cancer. 89:209–212. 2000. View Article : Google Scholar : PubMed/NCBI